Bayer has entered a significant collaboration with U.S. biotech company NextRNA to develop novel cancer therapies, committing up to $547 million. The deal, announced on Wednesday, includes upfront payments, success-based milestone payments, research funding, and tiered license fees. The partnership will focus on developing two oncology programs, with the first currently in early preclinical development at NextRNA.
This collaboration is crucial for Bayer as it seeks to replenish its pharmaceutical pipeline, particularly with the impending expiration of patents on key drugs like the anticoagulant Xarelto and the ophthalmic drug Eylea. Bayer's recent setbacks, including the failure of its anticoagulant Asundexian in a critical clinical trial, have increased the urgency to develop new successful therapies.
In addition to this deal, Bayer had earlier in March acquired the rights to a new heart drug, investing up to $310 million. These strategic moves underline Bayer's efforts to strengthen its pharmaceutical offerings as it prepares for the challenges posed by patent expirations on its current bestsellers.
Click here to read the original news story.